Dynavax Technologies Corporation (DVAX)
DVAX Stock Price Chart
Explore Dynavax Technologies Corporation interactive price chart. Choose custom timeframes to analyze DVAX price movements and trends.
DVAX Company Profile
Discover essential business fundamentals and corporate details for Dynavax Technologies Corporation (DVAX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
19 Feb 2004
Employees
405.00
Website
https://www.dynavax.comCEO
Ryan Spencer
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
DVAX Financial Timeline
Browse a chronological timeline of Dynavax Technologies Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 18 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is $0.14, while revenue estimate is $94.00M.
Earnings released on 7 Aug 2025
EPS came in at $0.14 surpassing the estimated $0.12 by +16.67%, while revenue for the quarter reached $95.44M , beating expectations by +1.48%.
Earnings released on 6 May 2025
EPS came in at -$0.11 falling short of the estimated $0.03 by -466.67%, while revenue for the quarter reached $68.16M , missing expectations by -19.00%.
Earnings released on 20 Feb 2025
EPS came in at $0.05 matching the estimated $0.05, while revenue for the quarter reached $72.03M , missing expectations by -0.92%.
Earnings released on 7 Nov 2024
EPS came in at $0.12 surpassing the estimated $0.11 by +9.09%, while revenue for the quarter reached $80.63M , beating expectations by +12.43%.
Earnings released on 6 Aug 2024
EPS came in at $0.08 surpassing the estimated $0.06 by +33.33%, while revenue for the quarter reached $73.80M , missing expectations by -3.03%.
Earnings released on 8 May 2024
EPS came in at -$0.07 falling short of the estimated -$0.05 by -40.00%, while revenue for the quarter reached $50.79M , missing expectations by -7.60%.
Earnings released on 22 Feb 2024
EPS came in at $0.00 surpassing the estimated $0.00 by +100.00%, while revenue for the quarter reached $55.60M , beating expectations by +5.46%.
Earnings released on 2 Nov 2023
EPS came in at $0.10 surpassing the estimated $0.01 by +766.55%, while revenue for the quarter reached $69.51M , beating expectations by +15.28%.
Earnings released on 3 Aug 2023
EPS came in at $0.03 surpassing the estimated -$0.09 by +133.33%, while revenue for the quarter reached $60.25M , beating expectations by +24.53%.
Earnings released on 2 May 2023
EPS came in at -$0.19 falling short of the estimated -$0.12 by -58.33%, while revenue for the quarter reached $46.93M , beating expectations by +21.60%.
Earnings released on 23 Feb 2023
EPS came in at $0.45 surpassing the estimated $0.43 by +4.65%, while revenue for the quarter reached $184.49M , beating expectations by +2.72%.
Earnings released on 3 Nov 2022
EPS came in at $0.43 surpassing the estimated $0.33 by +30.30%, while revenue for the quarter reached $167.74M , beating expectations by +5.22%.
Earnings released on 4 Aug 2022
EPS came in at $0.87 surpassing the estimated $0.22 by +295.45%, while revenue for the quarter reached $256.46M , beating expectations by +69.85%.
Earnings released on 5 May 2022
EPS came in at $0.22 falling short of the estimated $0.24 by -8.33%, while revenue for the quarter reached $113.99M , missing expectations by -26.12%.
Earnings released on 28 Feb 2022
EPS came in at $0.55 falling short of the estimated $0.69 by -20.29%, while revenue for the quarter reached $195.07M , missing expectations by -6.61%.
Earnings released on 4 Nov 2021
EPS came in at $0.06 surpassing the estimated $0.05 by +20.00%, while revenue for the quarter reached $108.27M , beating expectations by +126.46%.
Earnings released on 4 Aug 2021
EPS came in at $0.02 surpassing the estimated $0.01 by +155.10%, while revenue for the quarter reached $52.77M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at $0.01 surpassing the estimated $0.00 by +150.00%, while revenue for the quarter reached $83.34M , beating expectations by +40.98%.
Earnings released on 25 Feb 2021
EPS came in at -$0.14 surpassing the estimated -$0.24 by +41.67%, while revenue for the quarter reached $19.55M , beating expectations by +49.69%.
Earnings released on 5 Nov 2020
EPS came in at -$0.15 surpassing the estimated -$0.20 by +25.00%, while revenue for the quarter reached $13.41M , missing expectations by -80.00%.
DVAX Stock Performance
Access detailed DVAX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.